2020 Annual Primetime CME Symposia

Primetime Symposium

WEDNESDAY, OCTOBER 21, 2020 · 3:45 – 4:45 PM EASTERN TIME

ABC Access To Care Initiative: Overcoming Disparities and Gaps in the Diagnosis and Treatment of Familial Hypercholesterolemia

Chaired by: Keith C. Ferdinand, MD

Learning Objectives

After completing this activity, the participant should be better able to:

  • Define the FH pathophysiology, increased ASCVD risk with FH, and its clinical presentation
  • Utilize current and emerging diagnostic approaches aimed to optimize the early identification of patients with FH
  • Interpret the efficacy and safety of current and emerging therapeutic options for the treatment of FH
  • Employ strategies and resources aimed at improving the access of patients with FH to medically-necessary therapies
  • Develop individualized treatment regimens to lower LDL-C and address ASCVD risk in patients with FH, based on the current guidelines, including the 2018 ACC/AHA cholesterol guidelines, and evidence about statin and non-statin therapies
CMHC PIM

This activity is jointly provided by Postgraduate Institute for Medicine and CMHC. Multisupported by educational grants from Esperion Therapeutics, Inc. and Novartis Pharmaceuticals Corporation and in partnership with the Association of Black Cardiologists, Inc (ABC) and the FH Foundation.

This activity is approved for AMA PRA Category 1 Credits™. This activity is eligible for ABIM MOC, ACPE, ANCC and CDR credit, see final activity announcement for specific details. For overall accreditation information on CMHC Annual 2020, please click here.

Sunrise Symposium

THURSDAY, OCTOBER 22, 2020 · 7:00 – 8:00 AM EASTERN TIME

Preventing Adverse Cardiovascular and Limb Events in High-Risk Cardiometabolic Patients with Peripheral Artery Disease: Recent Trials and Advances

Chaired by: Marc P. Bonaca, MD

Learning Objectives

After completing this activity, the participant should be better able to:

  • Describe the pathophysiology and major complications of peripheral artery disease and the heightened risk in cardiometabolic patients.
  • Summarize the major findings and implications of trials evaluating the role of direct oral anticoagulants in the management of high-risk patients with stable PAD
  • Discuss recent data about the role of direct oral anticoagulants in patients with PAD who have undergone lower-extremity revascularization
  • Develop individualized strategies for the prevention of adverse cardiovascular and limb events in high-risk cardiometabolic patients with PAD.
CMHC PIM

This activity is jointly provided by Postgraduate Institute for Medicine and CMHC. Supported by an educational grant from Janssen Scientific Affairs, LLC.

This activity is approved for AMA PRA Category 1 Credits™. This activity is eligible for ABIM MOC, ACPE, ANCC and CDR credit, see final activity announcement for specific details. For overall accreditation information on CMHC Annual 2020, please click here.

Primetime Symposium

THURSDAY, OCTOBER 22, 2020 · 10:45 – 11:45 AM EASTERN TIME

The Challenge of Chronic Hyperkalemia in Cardiometabolic Patients: Advances and Opportunities

Chaired by: Matthew R. Weir, MD

Learning Objectives

After completing this activity, the participant should be better able to:

  • Identify patients at risk for hyperkalemia based on the presence of several modifiable risk factors
  • Summarize current guidelines for the use of RAASis in cardiometabolic patients in the setting of potential hyperkalemia
  • Interpret the efficacy and safety of current and new treatment options for hyperkalemia
  • Develop appropriate treatment regimens for the management of chronic hyperkalemia in patients with cardiometabolic disease or cardiometabolic risk
CMHC PIM

This activity is jointly provided by Postgraduate Institute for Medicine and CMHC. Supported by an educational grant from Relypsa, Inc.

This activity is approved for AMA PRA Category 1 Credits™. This activity is eligible for ABIM MOC, ACPE, ANCC and CDR credit, see final activity announcement for specific details. For overall accreditation information on CMHC Annual 2020, please click here.

Primetime Symposium

Thursday, October 22, 2020 · 2:50 – 3:50 PM EASTERN TIME

Tackling Diabetic Kidney Disease Progression: Challenges, Advances, and Novel Approaches

Chaired by: George L. Bakris, MD

Learning Objectives

After completing this activity, the participant should be better able to:

  • Identify T2DM patients at risk for kidney disease or kidney disease progression
  • Develop appropriate treatment options for patients with DKD based on current guideline recommendations and available treatment options
  • Summarize the efficacy, safety, and mechanisms of action of emerging treatment options for DKD
CMHC PIM

This activity is jointly provided by Postgraduate Institute for Medicine and CMHC. Supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

This activity is approved for AMA PRA Category 1 Credits™. This activity is eligible for ABIM MOC, ACPE, ANCC and CDR credit, see final activity announcement for specific details. For overall accreditation information on CMHC Annual 2020, please click here.

Primetime Symposium

FRIDAY, OCTOBER 23, 2020 · 8:45 –9:45 AM EASTERN TIME

The Evolving Landscape of LDL-C Reduction: Novel Therapies and Approaches

Chaired by: Christie M. Ballantyne, MD

Learning Objectives

After completing this activity, the participant should be better able to:

  • Recognize residual ASCVD risk that may persist even after maximally-tolerated statin therapy, ezetimibe, or PCSK9-inhibiting mAbs
  • Identify high-risk patients with elevated LDL-C and ASCVD who may not adequately respond or adhere to current therapy
  • Review the rationale, mechanisms of action, efficacy and safety of LDL-C lowering agents in advanced clinical development and their potential role in hypercholesterolemia management and ASCVD risk reduction
CMHC PIM

This activity is jointly provided by Postgraduate Institute for Medicine and CMHC. Supported by an educational grant from Esperion Therapeutics, Inc.

This activity is approved for AMA PRA Category 1 Credits™. This activity is eligible for ABIM MOC, ACPE, ANCC and CDR credit, see final activity announcement for specific details. For overall accreditation information on CMHC Annual 2020, please click here.

Primetime Symposium

FRIDAY, OCTOBER 23, 2020 · 1:50 – 2:50 PM EASTERN TIME

Preventing Cardiovascular Events in High-Risk Diabetes Patients with CAD: New Insights and Developments

Chaired by: Deepak L. Bhatt, MD, MPH

Learning Objectives

After completing this activity, the participant should be better able to:

  • Interpret the impact of diabetes on cardiovascular risk assessment
  • Summarize results of recent clinical trials about the efficacy and safety of novel antiplatelet approaches in the setting of primary CVD prevention in patients with diabetes and CAD.
  • Develop individualized treatment plans to prevent adverse CVD events in high-risk diabetes patients with CAD.
CMHC PIM

This activity is jointly provided by Postgraduate Institute for Medicine and CMHC. Supported by an educational grant from AstraZeneca.

This activity is approved for AMA PRA Category 1 Credits™. This activity is eligible for ABIM MOC, ACPE, ANCC and CDR credit, see final activity announcement for specific details. For overall accreditation information on CMHC Annual 2020, please click here.

Primetime Symposium

FRIDAY, OCTOBER 23, 2020 · 5:25 – 6:25 PM

Optimizing Postprandial Glucose Control in Patients with Diabetes: Clinical Advances and Strategies

Chaired by: Anne L. Peters, MD

Learning Objectives

After completing this activity, the participant should be better able to:

  • Identify practical dietary and lifestyle modifications as adjunct therapy in minimizing PPG excursions in insulin-treated patients
  • Outline the efficacy, safety, and appropriate use of faster acting insulins in the management of PPG
  • Summarize the different CGM platforms and their utility in optimizing PPG control
  • Develop individualized treatment plans to optimize PPG control in patients with diabetes, including the use of newer generation prandial insulins and CGM
CMHC PIM

This activity is jointly provided by Postgraduate Institute for Medicine and CMHC. Multisupported by educational grants from Medtronic and Dexcom, Inc.

This activity is approved for AMA PRA Category 1 Credits™. This activity is eligible for ABIM MOC, ACPE, ANCC and CDR credit, see final activity announcement for specific details. For overall accreditation information on CMHC Annual 2020, please click here.

Primetime General Session Symposium

SATURDAY, OCTOBER 24, 2020 · 10:15 – 10:35 AM EASTERN TIME

What BMI Should Be Used for Metabolic Surgery?

Chaired by: David E. Cummings, MD

Learning Objectives

After completing this activity, the participant should be better able to:

  • Summarize the efficacy and safety of metabolic surgery in improving cardiometabolic outcomes
  • Identify the need for bariatric surgery in their patients based on their BMI and other parameters such as cardiometabolic comorbidities, race, and gender
  • Develop individualized treatment options for patients with obesity and cardiometabolic risk that include comprehensive treatment approaches, including metabolic surgery
Anenberg Center for Health Sciences CMHC PIM

This activity is jointly provided by Annenberg Center for Health Sciences at Eisenhower and CMHC in collaboration with Postgraduate Institute for Medicine. Supported by an educational grant from Medtronic.

This activity is approved for AMA PRA Category 1 Credits™. This activity is eligible for ABIM MOC, ACPE, ANCC and CDR credit, see final activity announcement for specific details. For overall accreditation information on CMHC Annual 2020, please click here.